Roche leads pre-JPM deal spree; Roger Perl­mut­ter’s new phar­ma force; In­side Sage’s big tri­umph and fail­ure; Late Fri­day IPO fil­ings; All new drugs in 2023; and more

Wel­come to the first is­sue of End­points Week­ly in 2024! The year is start­ing strong, and there will be no short­age of top­ics for my …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.